THE 30-SECOND OVERVIEW
At a glance
Tesamorelin and ipamorelin are routinely discussed as interchangeable growth-hormone secretagogues. They are not the same class of molecule, they bind different receptors, and the volume of human evidence behind them differs by roughly two orders of magnitude. Comparing them usefully means separating the pharmacology from the evidence, because the two comparisons give different answers.
Two receptors, not one pathway
Tesamorelin is a growth hormone-releasing hormone analogue. It is a 44-amino-acid peptide, a modified form of human GHRH(1-44) carrying a trans-3-hexenoic acid group at the N-terminus, which slows degradation by dipeptidyl peptidase-4. It binds the GHRH receptor on pituitary somatotrophs.
Ipamorelin is a pentapeptide and a ghrelin receptor agonist, acting at GHS-R1a. Structurally it has nothing in common with tesamorelin. It belongs to the growth hormone-releasing peptide family, alongside GHRP-2 and GHRP-6. GHS-R1a is also the receptor of MK-677, the orally active small-molecule ghrelin mimetic stocked as a liquid, which is the non-peptide member of this family.
Both raise growth hormone. They arrive there through separate receptor systems, which is the stated rationale for the combination protocols that appear in the research literature: GHRH-receptor and ghrelin-receptor stimulation are not redundant, and preclinical work reports additive release when both are engaged.
Ipamorelin's distinguishing feature within its own family is selectivity. GHRP-6 and GHRP-2 stimulate growth hormone but also raise cortisol and prolactin at effective quantities. Published characterisation of ipamorelin reports growth hormone release without the same accompanying rise, which is the property it was developed for and the reason it appears in research protocols where the older GHRPs do not.
The evidence bases are not comparable
This is where the two compounds separate sharply, and where most side-by-side comparisons go wrong.
Tesamorelin has a substantial human clinical record. It ran two phase 3 randomised, placebo-controlled trials in HIV-associated lipodystrophy, enrolling roughly 800 participants combined, and it holds FDA approval for that indication under the name Egrifta. The trials measured visceral adipose tissue by CT, reported reductions in the range of 15-18% against placebo over 26 weeks, and documented IGF-1 response and adverse events across a defined population. Follow-on work examined the 26-52 week extension period and what happened after discontinuation.
Ipamorelin has almost none. It was characterised in animal models in the late 1990s, entered clinical development for postoperative ileus rather than any body-composition indication, and that programme was discontinued. There is no phase 3 dataset, no approved indication, and no long-term human safety record. What exists is preclinical pharmacology plus limited early-phase human work in an unrelated setting.
A comparison that presents these two as equivalent options with different mechanisms is describing the pharmacology accurately and the evidence base misleadingly. One compound has been studied in a defined human population to a regulatory standard. The other has not been studied in humans at any comparable depth.
What the tesamorelin trials used
The clinical literature converged on a consistent protocol: 2mg once daily by subcutaneous injection. Both phase 3 trials used this quantity, and the extension work continued it.
The trials measured a specific outcome in a specific population: visceral adipose tissue in HIV-associated lipodystrophy. That population had characteristics relevant to the result. Extrapolating the effect size to other populations is not something the trials support, and the published analyses are explicit about the indication studied.
IGF-1 rose in treated participants, as expected from the mechanism. The trials monitored it, and the labelling reflects that monitoring. Glucose parameters received particular attention given the population and the mechanism's known relationship to insulin sensitivity.
What the ipamorelin research used
Preclinical characterisation reported dose-dependent growth hormone release in animal models across a range spanning low microgram-per-kilogram quantities upward, with the selectivity profile described above holding across the studied range.
Because the human programme targeted postoperative ileus, its dosing was designed around gastrointestinal motility endpoints rather than growth hormone response or body composition. Those figures do not transfer to the contexts ipamorelin is usually discussed in, and the literature does not offer a substitute.
The consequence is that ipamorelin protocols circulating outside the literature are not derived from published human research. They are extrapolations from animal pharmacology, and they should be identified as such.
Half-life and administration differ substantially
Tesamorelin's modification is specifically about survival in circulation. Unmodified GHRH(1-44) is degraded rapidly by DPP-4; the hexenoic acid group slows this, which is what makes once-daily administration viable in the trial protocols.
Ipamorelin's half-life is short, reported in the region of two hours in the characterisation literature, and its pulsatile release profile reflects that. Research protocols involving it therefore tend to use more frequent administration than tesamorelin's once-daily schedule, which is a practical difference that follows directly from the pharmacokinetics rather than from any preference about the compounds.
Both are supplied lyophilised for research and require reconstitution. Neither survives oral administration intact, which is why the studied routes are parenteral.
What neither comparison establishes
Growth hormone response is a measured biochemical outcome. It is not the same as any downstream outcome, and the tesamorelin trials are a useful illustration of the gap: they measured visceral adipose tissue directly rather than inferring it from IGF-1, because the relationship between the two is not tight enough to substitute one for the other.
For ipamorelin, the absence of human outcome data means there is nothing to compare against tesamorelin's phase 3 results. Any comparison of effect is a comparison between a measured result and an absence of measurement.
Neither compound has published research supporting use outside a controlled setting, and both are supplied for research use only.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Falutz, J., Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370.
2. Falutz, J., Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter trials. Journal of Clinical Endocrinology and Metabolism, 95(9), 4291-4304.
3. Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
4. Egrifta (tesamorelin for injection) prescribing information. US Food and Drug Administration.
